预先皮肤处理以预防抗 EGFR 抗体引起的皮肤毒性：来自日本的真实世界证据。
Pre-emptive skin treatments to prevent skin toxicity caused by anti-EGFR antibody: the real-world evidence in Japan.
机构信息
Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
出版信息
Future Oncol. 2018 Dec;14(30):3163-3174. doi: 10.2217/fon-2018-0379. Epub 2018 Sep 14.
AIM
Clinically managing skin toxicity associated with anti-EGFR antibody usage to treat colorectal cancer improves quality of life for colorectal cancer patients. This study assesses trends of pre-emptive skin treatments and their impact on subsequent dermatologist visits in Japanese colorectal cancer patients.
PATIENTS & METHODS: Pre-emptive treatment status and dermatologist visit data were investigated for 9461 colorectal cancer patients who experienced anti-EGFR antibody treatment. Data were collected from an electronic hospital-based claims database.
RESULTS
Pre-emptive treatments increased around 2013. Furthermore, subsequent dermatologist visits decreased significantly among the pre-emptive treatment group (p < 0.05).
CONCLUSION
Pre-emptive skin treatments seem to be related to reducing subsequent dermatologist visits by severe skin toxicity prevention and gained popularity in Japan.
目的
临床管理与抗 EGFR 抗体治疗相关的皮肤毒性可提高结直肠癌患者的生活质量。本研究评估了日本结直肠癌患者预先皮肤治疗的趋势及其对随后皮肤科就诊的影响。
方法
对 9461 例接受抗 EGFR 抗体治疗的结直肠癌患者的预先治疗情况和皮肤科就诊数据进行了调查。数据来自电子医院基于索赔的数据库。
结果
预先治疗的使用在 2013 年左右有所增加。此外，预先治疗组的后续皮肤科就诊显著减少（p<0.05）。
结论
预防严重皮肤毒性的预防性皮肤治疗似乎与减少随后的皮肤科就诊有关，并在日本受到欢迎。
Zotero 插件